MedTrace Logo

Brivanib Metastatic Renal Cell Carcinoma

NCT01253668 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-04-13

Study results available
· View outcomes & findings →

Summary

This is a phase II study of an investigational agent, brivanib, in patients with refractory metastatic renal cell carcinoma. This study will evaluate the safety and effectiveness of brivanib in renal cell carcinoma, and explore the activity of this drug in this population to determine whether imaging and molecular features of the tumors can be used to predict response. Approximately 30 people with advanced kidney cancer will be enrolled on this study at the University of Pennsylvania.

Conditions

Interventions

DRUG

Brivanib alaninate

Brivanib by mouth daily at a dose of 800mg.

GENETIC

Polymerase chain reaction

Undergo 1241-cG250 PET/CT imaging (correlative studies)

OTHER

Iodine I 124 chimeric monoclonal antibody G250

Undergo 124I-cG250 PET/CT imaging (correlative studies)

PROCEDURE

Positron emission tomography/computed tomography

Undergo 1241-cG250 PET/CT imaging (correlative studies)

GENETIC

Protein expression analysis

Correlative studies

OTHER

Immunohistochemistry

correlative studies

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Stephen Keefe, MD · Abramson Cancer Center at Penn Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01253668 on ClinicalTrials.gov